1Research and Innovative Technology Administration,USDOT.International Deployment of Cooperative Intelligent Transportation Systems-Bilateral Efforts of theEuropean Commission and United States Department ofTransportation. http://www.its.dot.gov/connected_vehicle/pdf/Joint_EU-US_Report.pdf . 2012
4Krieg AM. Therapeutic potential of Toll like receptor 9 activation [ J ]. Nat Rev Drug Diseov,2006,5 ( 6 ) :471 - 484.
5Bauer S, Kirschning C J, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species- specific CpG motif recognition [ J ]. Proc Natl Acad Sci USA, 2001,98 (16) :9237 - 9242.
6Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates [ J ]. Clin Immunol,2003,109 ( 1 ) :64 - 71.
7Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA [ J]. Trends Mol Med, 2002,8(4) :114 - 121.
8Krieg AM, Yi AK, Schorr J, et al. The role of CpG denucleotides in DNA vaccine [ J ]. Trends Microbiol, 1998,6(1) :23 -27.
9Hartmann G,Weerantna RD,Ballas ZK,et al. Delineation of a CpG phosphorothioate oligodeoxynueleotide for activating primate immune responses in vitro and in vivo [ J ]. J Immmunol, 2000,164 ( 3 ) : 1617 - 1624.
10Takeshita S, Takeshita F, Haddad DE, et al. CpG oligodeoxynucleotides induce murine macrophages to up- regulate chemokine mRNA expression [ J ]. Cell Immunol,2000,206 (2) : 101 - 106.
